<DOC>
	<DOCNO>NCT01529372</DOCNO>
	<brief_summary>The REALISE trial single-arm , open-label , prospective , post market evaluation conduct twenty ( 20 ) eligible patient twelve month follow-up period .</brief_summary>
	<brief_title>REnAL denervatIon ultraSound Transcatheter Emission</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Resistant hypertension , defined 2007 ESHESC guideline 18 year age older Negative pregnancy test female patient childbearing potential Willing able comply followup requirement Signed informed consent Secondary hypertension Main renal artery length &lt; 20 mm Main renal artery diameter &lt; 4 mm Renal artery stenosis Iliac/femoral artery stenosis preclude insertion catheter Allergy contrast medium Currently participate study investigational drug device Hemodynamics abnormality Moderate severe renal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Blood pressure</keyword>
	<keyword>Renal denervation</keyword>
</DOC>